The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance
Cell · 2024-10 · 187 (21) · 6055-6070.e22
DOI: 10.1016/j.cell.2024.08.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-10. Verfasst von Justin L Engel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Chromothripsis, Fanconi Anemia. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Chromothripsis describes the catastrophic shattering of mis-segregated chromosomes trapped within micronuclei. Although micronuclei accumulate DNA double-strand breaks and replication defects throughout interphase, how chromosomes undergo shattering remains unresolved. Using CRISPR-Cas9 screens, we identify a non-canonical role of the Fanconi anemia (FA) pathway as a driver of chromothripsis. Inactivation of the FA pathway suppresses chromosome shattering during mitosis without impacting interphase-associated defects within micronuclei. Mono-ubiquitination of FANCI-FANCD2 by the FA core complex promotes its mitotic engagement with under-replicated micronuclear chromosomes. The structure-selective SLX4-XPF-ERCC1 endonuclease subsequently induces large-scale nucleolytic cleavage of persistent DNA replication intermediates, which stimulates POLD3-dependent mitotic DNA synthesis to prime shattered fragments for reassembly in the ensuing cell cycle. Notably, FA-pathway-induced chromothripsis generates complex genomic rearrangements and extrachromosomal DNA that confer acquired resistance to anti-cancer therapies. Our findings demonstrate how pathological activation of a central DNA repair mechanism paradoxically triggers cancer genome evolution through chromothripsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School…
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
- Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton CB10 1SD, UK; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam 3015 GD, the Netherlands.
- Laboratory of Genome Maintenance, Rockefeller University, New York, NY 10065, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Engel, J. L., Zhang, X., Wu, M., Wang, Y., Espejo Valle-Inclán, J., Hu, Q., Woldehawariat, K. S., Sanders, M. A., Smogorzewska, A., Chen, J., Cortés-Ciriano, I., Lo, R. S., & Ly, P. (2024). The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell, 187(21), 6055-6070.e22. https://doi.org/10.1016/j.cell.2024.08.001
Vancouver
Engel JL, Zhang X, Wu M, Wang Y, Espejo Valle-Inclán J, Hu Q, et al. The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell. 2024;187(21):6055-6070.e22. doi:10.1016/j.cell.2024.08.001
BibTeX
@article{Engel2024,
author = {Engel, Justin L and Zhang, Xiao and Wu, Mingming and Wang, Yan and Espejo Valle-Inclán, Jose and Hu, Qing and Woldehawariat, Kidist S and Sanders, Mathijs A and Smogorzewska, Agata and Chen, Jin and Cortés-Ciriano, Isidro and Lo, Roger S and Ly, Peter},
title = {The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance},
journal = {Cell},
year = {2024},
volume = {187},
number = {21},
pages = {6055--6070.e22},
doi = {10.1016/j.cell.2024.08.001}
}
EUVIMED